Literature DB >> 24533891

Drug-polymer miscibility across a spray dryer: a case study of naproxen and miconazole solid dispersions.

Zelalem Ayenew Worku1, Jolie Aarts, Abhishek Singh, Guy Van den Mooter.   

Abstract

The structural and physical stability of solid dispersions have not been adequately explored during spray drying manufacturing processes. In this study a wide range of compositions of naproxen/PVP-VA 64 (poly(1-vinylpyrrolidone-co-vinyl acetate)) and miconazole/PVP-VA 64 solid dispersions prepared by different laboratory spray dryers were collected from various selected locations and used to investigate the drug-polymer mixing across spray dryers. Spray-dried dispersions with 30% (w/w) naproxen collected from the transport tube of the Pro-C-epT Microspray dryer showed the narrowest glass transition width, which apparently indicates the highest degree of drug-polymer mixing compared to the other locations. The intensity of the naproxen-PVP-VA 64 interaction peak at 1654 cm(-1) of IR spectra differs for solid dispersions (SDs) from the collector and transport tube of Pro-C-epT Microspray dryer with a higher intensity for the latter. Samples with 50% (w/w) naproxen loading collected from the cyclone and the cyclone steel part of the Buchi mini spray dryer showed a melting endotherm (Tm at 112.2 ± 0.8 °C and ΔHf between 0.7 and 1.8 J/g), whereas samples from the cyclone tube to the drying chamber were devoid of crystalline material. The variations in drug-polymer mixing extend to miconazole/PVP-VA solid dispersions where 20% drug loading showed location-dependent drug-polymer mixing. This study clearly showed that the variation in drug-polymer miscibility and solid form of the drug in solid dispersions can occur across spray dryer in small-scale manufacturing processes. The optimization of formulation parameters and spray drying process parameters is imperative to diminish these variations to enhance homogeneity of solid dispersions in laboratory scale spray dryers. The same problem can occur in geometrically large spray drying manufacturing equipment, and the robustness of the processes should be carefully assessed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24533891     DOI: 10.1021/mp4003943

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Use of Spray-Dried Dispersions in Early Pharmaceutical Development: Theoretical and Practical Challenges.

Authors:  Jinjiang Li; Dhaval Patel; George Wang
Journal:  AAPS J       Date:  2016-11-28       Impact factor: 4.009

2.  Prediction of Phase Behavior of Spray-Dried Amorphous Solid Dispersions: Assessment of Thermodynamic Models, Standard Screening Methods and a Novel Atomization Screening Device with Regard to Prediction Accuracy.

Authors:  Aymeric Ousset; Pierre-François Chavez; Joke Meeus; Florent Robin; Martin Alexander Schubert; Pascal Somville; Kalliopi Dodou
Journal:  Pharmaceutics       Date:  2018-03-07       Impact factor: 6.321

3.  Amorphous Solid Dispersions and the Contribution of Nanoparticles to In Vitro Dissolution and In Vivo Testing: Niclosamide as a Case Study.

Authors:  Miguel O Jara; Zachary N Warnken; Robert O Williams
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

4.  Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.

Authors:  Jaya Mishra; Thomas Rades; Korbinian Löbmann; Holger Grohganz
Journal:  Pharmaceutics       Date:  2018-04-12       Impact factor: 6.321

5.  Water-Induced Phase Separation of Spray-Dried Amorphous Solid Dispersions.

Authors:  Na Li; Jonathan L Cape; Bharat R Mankani; Dmitry Y Zemlyanov; Kimberly B Shepard; Michael M Morgen; Lynne S Taylor
Journal:  Mol Pharm       Date:  2020-09-24       Impact factor: 4.939

6.  The Value of Bead Coating in the Manufacturing of Amorphous Solid Dispersions: A Comparative Evaluation with Spray Drying.

Authors:  Eline Boel; Felien Reniers; Wim Dehaen; Guy Van den Mooter
Journal:  Pharmaceutics       Date:  2022-03-11       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.